- Home
- AIRS vs IPHA Comparison
AIRS vs IPHA Comparison
Compare AIRS & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AIRS
- IPHA
- Stock Information
- Founded
- AIRS 2012
- IPHA 1999
- Country
- AIRS United States
- IPHA France
- Employees
- AIRS N/A
- IPHA N/A
- Industry
- AIRS Medical/Nursing Services
- IPHA Biotechnology: Pharmaceutical Preparations
- Sector
- AIRS Health Care
- IPHA Health Care
- Exchange
- AIRS Nasdaq
- IPHA Nasdaq
- Market Cap
- AIRS 166.3M
- IPHA 167.7M
- IPO Year
- AIRS 2021
- IPHA 2019
- Fundamental
- Price
- AIRS $3.80
- IPHA $1.90
- Analyst Decision
- AIRS Hold
- IPHA Strong Buy
- Analyst Count
- AIRS 2
- IPHA 3
- Target Price
- AIRS $3.75
- IPHA $5.00
- AVG Volume (30 Days)
- AIRS 1.9M
- IPHA 574.8K
- Earning Date
- AIRS 11-07-2025
- IPHA 09-17-2025
- Dividend Yield
- AIRS N/A
- IPHA N/A
- EPS Growth
- AIRS N/A
- IPHA N/A
- EPS
- AIRS N/A
- IPHA N/A
- Revenue
- AIRS $157,554,000.00
- IPHA $14,839,695.00
- Revenue This Year
- AIRS N/A
- IPHA $22.29
- Revenue Next Year
- AIRS $5.14
- IPHA $43.84
- P/E Ratio
- AIRS N/A
- IPHA N/A
- Revenue Growth
- AIRS N/A
- IPHA N/A
- 52 Week Low
- AIRS $1.53
- IPHA $1.41
- 52 Week High
- AIRS $12.00
- IPHA $3.51
- Technical
- Relative Strength Index (RSI)
- AIRS 28.56
- IPHA 44.24
- Support Level
- AIRS $3.41
- IPHA $1.80
- Resistance Level
- AIRS $4.37
- IPHA $1.92
- Average True Range (ATR)
- AIRS 0.80
- IPHA 0.13
- MACD
- AIRS -0.35
- IPHA -0.01
- Stochastic Oscillator
- AIRS 5.49
- IPHA 13.41
About AIRS AirSculpt Technologies Inc.
AirSculpt Technologies Inc is a national provider of body contouring procedures delivering a premium consumer experience under its brand Elite Body Sculpture. Elite Body Sculpture, provides custom body contouring using the proprietary AirSculpt method that removes unwanted fat in a minimally invasive procedure. The company has one operating and reportable segment, direct medical procedure services.
About IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.